Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis: A One‐Year Double‐Blind, Randomized, Placebo‐Controlled Trial Using High‐Resolution Peripheral Quantitative Computed Tomography
Arthritis & Rheumatology · 2025
DOI: 10.1002/art.43154 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Yingzhao Jin und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Chinese University of Hong Kong, Hong Kong. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Metacarpophalangeal Joint. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
This study aimed to ascertain the effect of secukinumab on erosion and enthesiophyte progression in psoriatic arthritis (PsA) by using high‐resolution peripheral quantitative computed tomography (HR‐pQCT).
Methods
This was a phase 4, double‐blind, randomized, placebo‐controlled trial. Patients with active PsA and ≥1 erosion in metacarpophalangeal joints (MCPJs) 2 to 4 were randomly assigned in a 1:1 ratio to subcutaneous secukinumab or placebo. HR‐pQCT of MCPJs 2 to 4 were performed at baseline, week 24, and week 48. The primary outcome was the changes in the volume of erosions on MCPJs 2 to 4 measured by HR‐pQCT at 24 and 48 weeks.
Results
Forty patients (mean ± SD age 51.9 ± 13.4 years, 20 [50%] male, mean ± SD disease duration 4.7 ± 6.7 years) were recruited. Thirty‐four patients who completed study treatment were included in the per‐protocol analysis. At baseline, week 24, and week 48, the secukinumab group showed a significant reduction in erosion volume, whereas no changes were observed in the placebo group (median change in the secukinumab group −0.1 [interquartile range −0.5 to 0.0] vs 0.0 [interquartile range −0.2 to 0.4] in the placebo group, P = 0.004). A similar trend was observed for enthesiophyte volume changes in the secukinumab group, whereas no differences were noted in the placebo group (median change in the secukinumab group −0.1 [interquartile range −0.8 to 0.0] vs 0.0 [interquartile range −0.4 to 1.3] in the placebo group, P = 0.067). Generalized estimating equations results showed that the odds ratio (OR) for enthesiophyte progression in the secukinumab group was 0.264 (95% confidence interval [CI] 0.080–0.878, P = 0.030), whereas the OR for partial erosion healing in the secukinumab group was 2.882 (95% CI 1.130–7.349, P = 0.027).
Conclusion
Secukinumab demonstrates a potential benefit in facilitating partial erosion repair and preventing enthesiophyte progression in PsA. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Chinese University of Hong Kong, Hong Kong.
- Tseung Kwan O Hospital, Hong Kong.
- Princess Margaret Hospital, Hong Kong.
- Queen Elizabeth Hospital, Hong Kong.
ORCID-Profile: Yingzhao Jin, Lai-Shan Tam
Zitieren
APA
Jin, Y., Cheng, I. T., So, H., Lai, B. T., Ying, S. K., Kwok, K. Y., Griffith, J., Hung, V., Szeto, C. C., Lee, J. J., Qin, L., & Tam, L. S. (2025). Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis: A One‐Year Double‐Blind, Randomized, Placebo‐Controlled Trial Using High‐Resolution Peripheral Quantitative Computed Tomography. Arthritis & Rheumatology. https://doi.org/10.1002/art.43154
Vancouver
Jin Y, Cheng IT, So H, Lai BT, Ying SK, Kwok KY, et al. Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis: A One‐Year Double‐Blind, Randomized, Placebo‐Controlled Trial Using High‐Resolution Peripheral Quantitative Computed Tomography. Arthritis & Rheumatology. 2025. doi:10.1002/art.43154
BibTeX
@article{Jin2025,
author = {Jin, Yingzhao and Cheng, Isaac T and So, Ho and Lai, Billy T and Ying, Shirley K and Kwok, Kitty Y and Griffith, James and Hung, Vivian and Szeto, Cheuk-Chun and Lee, Jack J and Qin, Ling and Tam, Lai-Shan},
title = {Effects of Secukinumab on Enthesiophyte and Erosion Progression in Psoriatic Arthritis: A One‐Year Double‐Blind, Randomized, Placebo‐Controlled Trial Using High‐Resolution Peripheral Quantitative Computed Tomography},
journal = {Arthritis & Rheumatology},
year = {2025},
doi = {10.1002/art.43154}
}
EUVIMED